Tumefactive demyelination: an approach to diagnosis and management (Q38075462)

28 August 2017

1 reference

title

Tumefactive demyelination: an approach to diagnosis and management (English)

1 reference

28 August 2017

Todd A Hardy

1

1 reference

PubMed ID

23334629

28 August 2017

Jeremy Chataway

series ordinal

2

1 reference

PubMed ID

23334629

28 August 2017

language of work or name

English

0 references

publication date

19 January 2013

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

28 August 2017

1 reference

28 August 2017

84

1 reference

28 August 2017

1047-1053

1 reference

28 August 2017

9

1 reference

Acute demyelinating disease. Classification and non-invasive diagnosis

28 August 2017

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

The pathological spectrum of CNS inflammatory demyelinating diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Tumefactive demyelinating lesions: nine cases and a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

The MRI appearance of tumefactive demyelinating lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Use of serial proton magnetic resonance spectroscopy to differentiate low grade glioma from tumefactive plaque in a patient with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Metabolic assessment of monofocal acute inflammatory demyelination using MR spectroscopy and (11)C-methionine-, (11)C-choline-, and (18)F-fluorodeoxyglucose-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Sentinel lesions of primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Is a "vanishing tumor" always a lymphoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Long-term follow-up of vanishing tumors in the brain: how should a lesion mimicking primary CNS lymphoma be managed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Evolution and long term outcome in patients presenting with large demyelinating lesions as their first clinical event.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Primary Sjögren Syndrome with tumefactive central nervous system involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Tumefactive demyelination-an unusual neurological presentation of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Negative association of Epstein-Barr virus or herpes simplex virus-1 with tumefactive central nervous system inflammatory demyelinating disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Repeated non-enhancing tumefactive lesions in a patient with a neuromyelitis optica spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Tumefactive demyelination associated with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Tumefactive demyelination, an uncommon form of tacrolimus neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Relapsing-remitting tumefactive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Demyelinating pseudotumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Rituximab for tumefactive inflammatory demyelination: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Multiple sclerosis: pseudotumoral forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Tumefactive multiple sclerosis lesions under fingolimod treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

A giant MS plaque mimicking PML during natalizumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

Natural history of multiple sclerosis: implications for counselling and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304498

21 January 2018

Identifiers

DOI

10.1136/JNNP-2012-304498

1 reference

28 August 2017

1 reference

PubMed ID

23334629